AOD-9604 Research: Mechanism, Studies, and the Null Human Trial

The short version

The AOD-9604 research splits into two columns that do not match. In the lab — mostly mice, rats, and cells — the fragment behaves as designed: it stops fat cells from building new fat (by blocking an enzyme called acetyl-CoA carboxylase, the gatekeeper of fat synthesis) and pushes them to burn more ^[4][1]. Obese mice given it lost weight and fat ^[1][2]. It does all this without plugging into growth hormone's receptor, so it does not raise IGF-1 (a growth signal) ^[1][3]. Then comes the human column: in about six trials of roughly 900 adults, it did not produce real weight loss versus a placebo, and the obesity program was stopped ^[12]. There is also early cartilage work in rabbits ^[10]. This page posts each finding to the study behind it, and flags whether each entry is from animals or from people.

How AOD9604 inhibits fat synthesis (acetyl-CoA carboxylase)

The foundational mechanism is antilipogenic — suppressing the synthesis of new fat — rather than directly lipolytic. Human growth hormone and its C-terminal part-sequence (hGH 172-191) inhibit acetyl-CoA carboxylase (ACC), and hence fatty-acid synthesis, by interacting with adipocyte and hepatocyte plasma membranes and releasing a second messenger that increases the enzyme's phosphorylation ^[4]. AOD-9604 was engineered around this domain ^[3].

Metabolic studies localised the fat-metabolism activity of growth hormone to this synthetic C-terminal AOD-9604 domain, supporting the C-terminal region as the functional unit responsible for the hormone's effects on lipid metabolism ^[3]. Earlier work in the same lineage documented effects of an antilipogenic hGH fragment on glucose transport in rat adipocytes ^[18] and the lipid-metabolism actions of a related structural domain (AOD9401) in Zucker fatty rats ^[19].

Beta-3 adrenergic receptors and fat oxidation in mice

After 14 days of chronic intraperitoneal treatment, both human growth hormone and AOD-9604 reduced body weight and fat in obese mice and increased beta-3 adrenergic receptor (beta3-AR) RNA expression in white adipose tissue ^[1]. In beta3-AR knockout mice the chronic weight/lipolytic response was abolished, while acute increases in energy expenditure and fat oxidation persisted — placing the long-term effect downstream of functional beta3-AR signalling ^[1].

A companion study reported that chronic treatment with growth hormone or the modified C-terminal fragment increased fat oxidation and produced weight loss in obese mice, shifting the respiratory quotient toward lipid utilisation ^[2]. This is the strongest column of the AOD-9604 ledger — reproducible, mechanistically anchored fat-metabolism effects. The flag on every one of these entries reads PRECLINICAL.

AOD-9604 weight loss: the human obesity program

AOD-9604 weight loss in humans is the entry that did not balance. Across roughly six randomised, double-blind, placebo-controlled trials totalling about 900 obese adults — oral daily doses from 0.25 mg to 54 mg, durations from 7 days to 24 weeks (a 24-week study used 0.25, 0.5, and 1 mg/day) — safety and tolerability were reported as indistinguishable from placebo and free of full-length-growth-hormone adverse effects ^[5]. But the pivotal Phase IIb obesity trial did not demonstrate statistically significant weight loss versus placebo, and the obesity development program was discontinued around 2007 ^[12][14].

This is the preclinical-to-human translational gap in one compound: strong rodent fat-metabolism data did not become sufficient clinical weight-loss efficacy — a common pattern among obesity drug candidates ^[13][14]. The foundational literature also characterised the fragment as primarily antilipogenic rather than directly lipolytic, so popular "fat-burning peptide" marketing overstates the directly-lipolytic framing ^[3].

AOD9604 peptide: pharmacokinetics, cartilage, and detection

On pharmacokinetics, the AOD9604 peptide is cleared rapidly: a very short half-life of about 3 minutes after intravenous injection in a pig model, with in-vivo degradation by sequential removal of amino acids from the N-terminus ^[6]. Oral absorption was demonstrated, and non-clinical evaluation found no genotoxic or toxicological concerns in rats and primates ^[6].

A secondary, preclinical-only line of work examined cartilage. In a collagenase-induced knee osteoarthritis model in 32 New Zealand white rabbits, weekly intra-articular injection of 0.25 mg AOD-9604 per knee (with or without 6 mg hyaluronic acid) for 4-7 weeks reduced gross morphological and histopathological cartilage-degeneration scores versus saline ^[10]. There are no published human osteoarthritis trials of AOD-9604 itself. Separately, anti-doping researchers have characterised AOD-9604 within the analytical scope of mass-spectrometric surveillance ^[16][17], and Belgian authorities documented it in seized, unregulated preparations ^[20].